Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 3, 2013, Pages 319-324

  Tsuruoka, Shuichi ^a   Yokota, Noritsugu ^b   Hayasaka, Tokie ^b   Saito, Tetsuo ^b   Yamagata, Kunihiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Moka Hospital   (Japan)

Author keywords

Antibiotics; Hemodialysis patients; Pharmacokinetics

Indexed keywords

ALBUMIN; CREATININE; SITAFLOXACIN;

ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL KIDNEY; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RENAL DIALYSIS; SERUM ALBUMIN; UREA;

EID: 84878711704     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01150.x     Document Type: Article

References (19)

1. U.S. Renal Data System. Annual Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, 2006.
2. Nakai S, Suzuki K, Masakane I etal. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010;14:505-40.
3. Onodera Y, Uchida Y, Tanaka M, Sato K. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999;44:533-6.
4. Visalli MA, Jacobs MR, Appelbaum PC. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40:362-6.
5. Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 2008;44:489-501.
6. Suzuki Y, Nakajima C, Tamaru A, Kim H, Matsuba T, Saito H. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. Int J Antimicrob Agents 2012;39:435-9.
7. Keating GM. Sitafloxacin: in bacterial infections. Drugs 2011;71:731-44.
8. O'Grady J, Briggs A, Atarashi S etal. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 2001;31:811-22.
9. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995;39:170-4.
10. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007;46:997-1038.
11. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-13.
12. Passey RB, Gillum RL, Fuller JB, Urry FM, Baron ML. Evaluation of three methods for the measurement of urea nitrogen in serum as used on six instruments. Am J Clin Pathol 1980;73:362-8.
13. Gabutti L, Taminelli-Beltraminelli L, Marone C. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers. Eur J Clin Pharmacol 1997;53:123-6.
14. Tsuruoka S, Sugimoto KI, Hayasaka T, Saito T, Fujimura A. Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. Eur J Clin Pharmacol 2000;56:581-3.
15. Tsuruoka S, Kitoh Y, Kawaguchi A etal. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril. J Clin Pharmacol 2007;47:259-63.
16. Tsuruoka S, Yokota N, Hayasaka T, Saito T, Yamagata K. Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients. Am J Kidney Dis 2011;58:498-9.
17. Lam YW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57.
18. Tachibana M, Tanaka M, Mitsugi K, Jin Y, Takaichi M, Okazaki O. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys. Arzneimittelforschung 2004;54:898-905.
19. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992;20:354-60.